Welcome to our dedicated page for Agios Pharmaceuticals news (Ticker: AGIO), a resource for investors and traders seeking the latest updates and insights on Agios Pharmaceuticals stock.
Agios Pharmaceuticals, Inc. (Nasdaq: AGIO) generates frequent news as a commercial-stage biopharmaceutical company focused on rare diseases, particularly rare blood disorders. Company updates often center on clinical trial results, regulatory decisions, commercial launches, and financial performance related to its portfolio of small-molecule therapies such as mitapivat.
Readers following AGIO news can expect detailed coverage of developments in the PK activation franchise, including mitapivat in thalassemia, sickle cell disease, and pyruvate kinase (PK) deficiency. Recent announcements have highlighted U.S. Food and Drug Administration (FDA) approval of AQVESME (mitapivat) for anemia in adults with alpha- or beta-thalassemia, positive CHMP opinions in Europe for PYRUKYND (mitapivat) in thalassemia, and topline results from the RISE UP Phase 3 trial in sickle cell disease.
News items also include financial results, such as quarterly revenue from PYRUKYND, updates on cash and investment balances, and commentary on research and development spending. Corporate communications frequently discuss anticipated milestones for ongoing trials of tebapivat, AG-236, and AG-181, as well as strategic priorities to advance Agios’ rare disease portfolio.
Investors and observers can use this page to track AGIO press releases on regulatory interactions, Risk Evaluation and Mitigation Strategy (REMS) implementation for AQVESME, partnerships for commercialization in Europe and the Middle East, and presentations at major medical and investor conferences. Bookmark this news feed to monitor how clinical data, approvals, and commercial execution shape the outlook for Agios Pharmaceuticals within the rare disease and hematology landscape.
Agios (Nasdaq: AGIO) announced EDE approval of PYRUKYND (mitapivat) on March 2, 2026 for adults with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia in the United Arab Emirates.
The approval makes PYRUKYND the only medicine authorized in the UAE for this adult thalassemia population and is based on global Phase 3 ENERGIZE and ENERGIZE-T trial results. NewBridge Pharmaceuticals will continue regional commercialization across the Gulf, following an existing GCC distribution agreement.
Agios (Nasdaq: AGIO) reported Q4 2025 results and business updates on Feb 12, 2026. Key highlights include AQVESME FDA approval and U.S. availability for thalassemia, PYRUKYND Q4 net revenue $20.0M ($16.0M U.S., $4.0M ex-U.S.), full-year PYRUKYND revenue $54.0M, and $1.2B cash as of Dec 31, 2025.
The company recorded a $108.0M Q4 net loss, plans a pre-sNDA FDA meeting for mitapivat in sickle cell disease in Q1 2026, and expects tebapivat Phase 2 topline data in H2 2026.
Agios (Nasdaq: AGIO) will host a conference call and live webcast on Thursday, February 12, 2026 at 8:00 a.m. ET to report fourth quarter and full year 2025 financial results and business highlights. The live webcast will be available on the company’s Investors website under the "Events & Presentations" tab. A replay will be posted on the company website approximately two hours after the event.
Agios (Nasdaq: AGIO) outlined 2026 strategic priorities focused on commercializing AQVESME (mitapivat) in thalassemia and advancing a pipeline of rare-disease programs.
Key points: AQVESME received U.S. FDA approval in December 2025 for anemia in adults with alpha- or beta-thalassemia and is expected to be available in the U.S. in late January 2026 after REMS implementation. Agios plans a pre-sNDA FDA meeting for mitapivat in sickle cell disease in Q1 2026 with a planned U.S. regulatory submission to follow. Multiple topline readouts are expected across 2026 for tebapivat, AG-236, and AG-181. The company projects a clear path to profitability and cites potential for over $1 billion in peak global sales from its PK activation franchise.
Agios (Nasdaq: AGIO) announced its management will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 at 8:15 a.m. PST / 11:15 a.m. EST. The presentation will be available via a live webcast on the company’s Investors site under “Events & Presentations.” A replay will be archived on the company website for at least two weeks after the presentation.
Agios (Nasdaq: AGIO) announced U.S. FDA approval of AQVESME™ (mitapivat) for treatment of anemia in adults with alpha- or beta-thalassemia, covering both non-transfusion-dependent and transfusion-dependent patients.
The approval is based on the randomized ENERGIZE and ENERGIZE-T Phase 3 trials (total 452 patients) that met primary and key secondary endpoints, showing improvements in hemoglobin, fatigue, and transfusion burden. AQVESME will be available in the U.S. in late January 2026 after implementation of an FDA REMS requiring liver tests and education. Five patients experienced adverse reactions suggestive of hepatocellular injury, with two hospitalizations; liver tests improved after discontinuation.
Agios (Nasdaq: AGIO) announced that the U.S. FDA has not issued a regulatory decision on the supplemental NDA for mitapivat in adult non‑transfusion‑dependent and transfusion‑dependent alpha‑ or beta‑thalassemia; the application remains under active review.
The FDA's PDUFA goal date was December 7, 2025. Agios said the agency has not requested, and the company has not submitted, any new efficacy or safety data, and that the companies are collaborating to finalize labeling and REMS materials. The FDA has not provided a timeline for its decision and Agios continues to work expeditiously to conclude the review.
Agios (Nasdaq: AGIO) reported topline 52-week RISE UP Phase 3 results for mitapivat in patients ≥16 with sickle cell disease. The trial met the primary hemoglobin response endpoint: 40.6% responders on mitapivat vs 2.9% on placebo (2-sided p<0.0001). Statistically significant improvements were also seen in average hemoglobin concentration (+7.69 g/L vs +0.26 g/L) and indirect bilirubin (-16.03 µmol/L vs +0.88 µmol/L) (both p<0.0001). The trial did not achieve statistical significance for annualized SCPC rate (2.62 vs 3.05, p=0.1213) or PROMIS Fatigue (p=0.7112). Safety was consistent with prior studies. Agios plans FDA engagement and intends an sNDA submission after a Q1 2026 pre-sNDA meeting.
Agios (Nasdaq: AGIO) will present new clinical and preclinical mitapivat data at the 67th ASH Annual Meeting, Dec 6–9, 2025 in Orlando.
Key highlights include a subgroup from ENERGIZE-T showing 77.8% (7/9) transfusion-reduction response in alpha-thalassemia versus 0% (0/3) placebo; long-term transfusion-free mean duration of 30.5 weeks (max 84.3 weeks) among 17 patients; and Phase 3 ACTIVATE-Kids meeting its primary hemoglobin endpoint with safety consistent with adult data. Ten Agios-led or collaborator presentations will be shared, plus advisory-council research on patient knowledge and fatigue impacts.
Agios (Nasdaq: AGIO) reported third quarter 2025 results and program updates on Oct 30, 2025. PYRUKYND net product revenue was $12.9M in Q3 2025, up 44% year‑over‑year. The FDA set a PDUFA goal date of Dec 7, 2025 for the PYRUKYND sNDA in thalassemia after requesting a REMS; CHMP adopted a positive opinion and an EC decision is expected by early 2026. Saudi Arabia approved PYRUKYND for thalassemia and commercial launch is underway there.
Topline results from the RISE UP Phase 3 sickle cell trial are expected by year‑end 2025, with a potential U.S. launch in 2026. The Phase 2b tebapivat LR‑MDS trial completed enrollment; topline data expected in early 2026. Cash, cash equivalents and marketable securities were $1.3B as of Sept 30, 2025.